Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
8 "Mauro Orlando"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
Cancer Res Treat. 2017;49(4):937-946.   Published online January 6, 2017
DOI: https://doi.org/10.4143/crt.2016.423
AbstractAbstract PDFPubReaderePub
Purpose
The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+GC among East Asian (EA) patients enrolled in the study.
Materials and Methods
All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m²) and cisplatin (day 1, 75 mg/m²). Patients in the neci+GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models.
Results
In EA patients, there were improvements for neci+GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade ≥ 3 AEs, and AEs with an outcome of death for neci+GC versus GC in EA patients and EA patients versus non-EA patients for neci+GC.
Conclusion
Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC.

Citations

Citations to this article as recorded by  
  • Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
    The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, Thi Thu Thao Mai, Phuong Tran Nhat, Kathirvel Brindhadevi, Arivalagan Pugazhendhi
    Process Biochemistry.2021; 104: 55.     CrossRef
  • Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis
    Irena Ilic, Sandra Sipetic, Jovan Grujicic, Milena Ilic
    Journal of Oncology Pharmacy Practice.2020; 26(6): 1331.     CrossRef
  • Recent progress in systemic treatment for lung cancer
    Jeffrey W. Clark, Dan L. Longo
    Current Opinion in Pulmonary Medicine.2018; 24(4): 355.     CrossRef
  • Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
    Vincenzo di Noia, Ettore D’Argento, Sara Pilotto, Giulia Grizzi, Mario Caccese, Roberto Iacovelli, Giampaolo Tortora, Emilio Bria
    Expert Opinion on Biological Therapy.2018; 18(9): 937.     CrossRef
  • SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
    Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, Fiona Blackhall, Noor Md Haris, Colin R Lindsay, Raffaele Califano, Mark Voskoboynik, Yvonne Summers, Karen So, Dana Ghiorghiu, Angela W Dymond, Stuart Hossack, Ruth Plummer, Emma Dean
    British Journal of Cancer.2017; 117(7): 938.     CrossRef
  • 10,978 View
  • 402 Download
  • 8 Web of Science
  • 5 Crossref
Close layer
Review Article
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Res Treat. 2017;49(4):851-868.   Published online January 3, 2017
DOI: https://doi.org/10.4143/crt.2016.176
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.

Citations

Citations to this article as recorded by  
  • The Potential Impact of Renin–Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis
    Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid
    Journal of Cardiovascular Pharmacology.2025; 85(1): 35.     CrossRef
  • Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis
    Liang Wang, Juyuan Li, Huamin Chen
    Chemotherapy.2024; 69(1): 11.     CrossRef
  • Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
    Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, Anidrisha Sahu, Darin M. Mathkor, Shafiul Haque, Deepika Raina, Seema Ramniwas, Madhu Gupta, Hardeep S. Tuli
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
    Huina Wang, Qingzhu Ding, Haihua zhou, Chuanjiang Huang, Guiyuan Liu, Xiaojun Zhao, Zhiyi Cheng, Xiaolan You
    Phytomedicine.2024; 134: 155962.     CrossRef
  • Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
    Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
    Cancer Medicine.2023; 12(7): 7784.     CrossRef
  • Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
    Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510
    Anica Högner, Salah‐Eddin Al‐Batran, Jens T. Siveke, Mario Lorenz, Prisca Bartels, Kirstin Breithaupt, Peter Malfertheiner, Nils Homann, Alexander Stein, Dietrich Gläser, Ingo Tamm, Axel Hinke, Arndt Vogel, Peter Thuss‐Patience
    International Journal of Cancer.2022; 150(6): 1007.     CrossRef
  • Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
    Linyan Zhang, Simeng Qin, Liuyi Lu, Li Huang, Shan Li
    The International Journal of Biological Markers.2022; 37(1): 66.     CrossRef
  • Tumor vessel normalization and immunotherapy in gastric cancer
    Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
    Yanling Ai, Ziyi Zhao, Hengyi Wang, Xiaomei Zhang, Weihan Qin, Yanlei Guo, Maoyuan Zhao, Jianyuan Tang, Xiao Ma, Jinhao Zeng
    Phytotherapy Research.2022; 36(9): 3371.     CrossRef
  • Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
    Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
    RSC Advances.2022; 12(34): 21821.     CrossRef
  • Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, Renuka Coudhary, Diwakar Aggarwal, Manoj Kumar, Ujjawal Sharma, Nidarshana Chaturvedi Parashar, Shafiul Haque, Katrin Sak
    Molecules.2022; 27(21): 7653.     CrossRef
  • Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis
    Yanjun Mi, Yongwen Li, Zhuo He, Donghan Chen, Qingqi Hong, Jun You
    Cancer Management and Research.2021; Volume 13: 899.     CrossRef
  • Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
    Shucheng Chen, Lan Yao
    Cancer Chemotherapy and Pharmacology.2021; 88(2): 323.     CrossRef
  • Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC
    Yuanyuan Ma, Xinyu Su, Xin Li, Xiaohui Zhi, Kan Jiang, Jianhong Xia, Hongliang Li, Chen Yan, Liqing Zhou
    Scientific Reports.2021;[Epub]     CrossRef
  • Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
    Xing Kang, En Xu, Xingzhou Wang, Lulu Qian, Zhi Yang, Heng Yu, Chao Wang, Chuanfu Ren, Yizhou Wang, Xiaofeng Lu, Xuefeng Xia, Wenxian Guan, Tong Qiao
    Cell Death & Disease.2021;[Epub]     CrossRef
  • A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
    Lin Li, Yuexian Li, Huawei Zou
    PeerJ.2021; 9: e12356.     CrossRef
  • Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hi
    Journal of Gastroenterology.2020; 55(6): 627.     CrossRef
  • The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
    Shahrzad S. Fard, Kioomars Saliminejad, Masoud Sotoudeh, Niloofar Soleimanifard, Shaghayegh Kouchaki, Mansour Yazdanbod, Habibollah Mahmoodzadeh, Ardeshir Ghavamzadeh, Reza Malekzadeh, Bahram Chahardouli, Kamran Alimoghaddam, Seyed H. Ghaffari
    Anti-Cancer Agents in Medicinal Chemistry.2020; 19(17): 2097.     CrossRef
  • Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, Ilaria Maggio, Maria Massucci, Fabiola Lorena Rojas Limpe, Francesca Di Fabio, Andrea Ardizzoni
    Future Oncology.2020; 16(2): 4409.     CrossRef
  • S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
    Chu Zhang, Guang-Mao Yu, Miao Zhang, Dong Liu
    Medicine.2020; 99(1): e18691.     CrossRef
  • An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
    Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianf
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
    Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun
    International Journal of Clinical Oncology.2020; 25(6): 1195.     CrossRef
  • Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He, Mingyan E
    Expert Review of Clinical Pharmacology.2020; 13(12): 1423.     CrossRef
  • Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
    Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
    Journal of Gastrointestinal Cancer.2019; 50(3): 556.     CrossRef
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
    Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai
    Journal of Gastrointestinal Cancer.2019; 50(4): 943.     CrossRef
  • Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
    Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
    Drug Safety.2019; 42(2): 159.     CrossRef
  • VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
    Lian Lian, Xiang-Li Li, Meng-Dan Xu, Xian-Min Li, Meng-Yao Wu, Yan Zhang, Min Tao, Wei Li, Xiao-Ming Shen, Chong Zhou, Min Jiang
    BMC Cancer.2019;[Epub]     CrossRef
  • STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB
    O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko
    Research and Practical Medicine Journal.2019; 6(3): 20.     CrossRef
  • Tumor progression-dependent angiogenesis in gastric cancer and its potential application
    Hsi-Lung Hsieh, Ming-Ming Tsai
    World Journal of Gastrointestinal Oncology.2019; 11(9): 686.     CrossRef
  • Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
    Guohui Liu, Chunbo Wang, Yunlong He, Mingyan E
    BMC Pharmacology and Toxicology.2019;[Epub]     CrossRef
  • N-methyl-N-nitro-N-nitrosoguanidine-mediated ING4 downregulation contributed to the angiogenesis of transformed human gastric epithelial cells
    Yansu Chen, Rui Fu, Mengdie Xu, Yefei Huang, Guixiang Sun, Lichun Xu
    Life Sciences.2018; 199: 179.     CrossRef
  • GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
    Keshuo Ding, Sheng Tan, Xing Huang, Xiaonan Wang, Xiaocan Li, Rong Fan, Yong Zhu, Peter E. Lobie, Wenbin Wang, Zhengsheng Wu
    Journal of Biological Chemistry.2018; 293(11): 3949.     CrossRef
  • Nanoparticles designed to regulate tumor microenvironment for cancer therapy
    Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou, Wei Wang
    Life Sciences.2018; 201: 37.     CrossRef
  • Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
    Xiaodong Wang, Yu Liu, Yuwen Diao, Ningning Gao, Yanyan Wan, Jingjing Zhong, Huali Zheng, Zhulin Wang, Guangyi Jin
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer
    In-Hwan Kim
    Annals of Surgical Oncology.2018; 25(S3): 749.     CrossRef
  • Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
    Mingzhe Lin, Xin Li, Haizhou Guo, Faxiang Ji, Linhan Ye, Xuemei Ma, Wen Cheng
    Current Bioinformatics.2018; 14(1): 62.     CrossRef
  • Antiangiogenic effects of oridonin
    Lili Tian, Kangjie Xie, Donglai Sheng, Xiaoqing Wan, Guofu Zhu
    BMC Complementary and Alternative Medicine.2017;[Epub]     CrossRef
  • The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
    Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad A. M. Al Mazeedi, Hashim A. M. Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S. Pepper, M. Iqbal Parker, Kevin Dzobo
    International Journal of Molecular Sciences.2017; 18(7): 1586.     CrossRef
  • Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
    Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
    Scientific Reports.2017;[Epub]     CrossRef
  • Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
    Henrik Nienhüser, Thomas Schmidt
    International Journal of Molecular Sciences.2017; 19(1): 43.     CrossRef
  • 17,218 View
  • 922 Download
  • 46 Web of Science
  • 41 Crossref
Close layer
Original Article
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando
Cancer Res Treat. 2016;48(4):1177-1186.   Published online February 22, 2016
DOI: https://doi.org/10.4143/crt.2015.401
AbstractAbstract PDFPubReaderePub
Purpose
REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients with disease progression following platinum-based chemotherapy. Results from the East Asian subgroup analysis are reported.
Materials and Methods
Subgroup analyses were performed in the East Asian ITT population (n=89). Kaplan-Meier analysis and Cox proportional hazards regression were performed for OS and PFS, and the Cochran-Mantel-Haenszel test was performed for response rate.
Results
In docetaxel+ramucirumab (n=43) versus docetaxel+placebo (n=46), median OS was 15.44 months versus 10.17 months (hazard ratio [HR], 0.762; 95% confidence interval [CI], 0.444 to 1.307), median PFS was 4.88 months versus 2.79 months (HR, 0.658; 95% CI, 0.408 to 1.060), and ORR was 25.6% (95% CI, 13.5 to 41.2) versus 8.7% (95% CI, 2.4 to 20.8). Due to increased incidence of neutropenia and febrile neutropenia in East Asian patients, starting dose of docetaxel was reduced for newly enrolled East Asian patients (75 to 60 mg/m2, n=24). In docetaxel+ramucirumab versus docetaxel+placebo, incidence of neutropenia was 84.4% versus 72.7% (75 mg/m2) and 54.5% versus 38.5% (60 mg/m2). Incidence of febrile neutropenia was 43.8% versus 12.1% (75 mg/m2) and 0% versus 7.7% (60 mg/m2).
Conclusion

Results
of this subgroup analysis showed a trend favoring ramucirumab+docetaxel for median OS, PFS, and improved ORR in East Asian patients, consistent with ITT population results. Reduction of starting dose of docetaxel in East Asian patients was associated with improved safety.

Citations

Citations to this article as recorded by  
  • Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
    Samuel A. Kareff, Kunal Gawri, Khadeja Khan, Deukwoo Kwon, Estelamari Rodriguez, Gilberto de Lima Lopes, Richa Dawar
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
    Yu Yang Soon, Wesley Furnback, Jin Kim, Po-Ya Chuang, Gordon Chavez, Christina Proescholdt, Cloe Ying Chee Koh
    JTO Clinical and Research Reports.2023; 4(11): 100579.     CrossRef
  • Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan
    Yucherng Chen, Soshi Nagaoka, Taeko Katayose, Nobuyuki Sekine
    Expert Opinion on Drug Safety.2022; 21(5): 691.     CrossRef
  • Validity of the Cancer and Aging Research Group Predictive Tool in Older Japanese Patients
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Cancers.2022; 14(9): 2075.     CrossRef
  • Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan
    Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Aki Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi
    Supportive Care in Cancer.2022; 30(8): 6775.     CrossRef
  • Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
    Yuankai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Caicun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Yin
    Cancer Communications.2022; 42(12): 1314.     CrossRef
  • The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel
    Yukie Omori, Sotaro Enatsu, Alan J.M. Brnabic, Narayan Rajan, Jin-Yuan Shih, Joo-Hang Kim, Keunchil Park, Akira Inoue
    Haigan.2019; 59(7): 1140.     CrossRef
  • Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
    Mark A. Socinski, Coleman Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. S
    Journal of Thoracic Oncology.2018; 13(2): 165.     CrossRef
  • Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
    Stefano Frega, Laura Bonanno, Valentina Guarneri, Pierfranco Conte, Giulia Pasello
    Critical Reviews in Oncology/Hematology.2018; 128: 19.     CrossRef
  • Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
    Chia-Jui Yen, Kei Muro, Tae-Won Kim, Masatoshi Kudo, Jin-Yuan Shih, Keun-Wook Lee, Yee Chao, Sang-We Kim, Kentaro Yamazaki, JooHyuk Sohn, Rebecca Cheng, Yawei Zhang, Polina Binder, Gu Mi, Mauro Orlando, Hyun Cheol Chung
    Journal of Global Oncology.2018; (4): 1.     CrossRef
  • Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
    Cancer Research and Treatment.2018; 50(3): 691.     CrossRef
  • The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
    Takumi Fujiwara, Hirotsugu Kenmotsu, Tateaki Naito, Takahisa Kawamura, Nobuaki Mamesaya, Mie Kotake, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira, Haruyasu Murakami, Katsuhiro Omae, Keita Mori, Masahiro E
    Cancer Chemotherapy and Pharmacology.2017; 79(6): 1229.     CrossRef
  • The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer
    Valérie Paulus, Virginie Avrillon, Maurice Pérol
    Expert Review of Anticancer Therapy.2016; 16(11): 1119.     CrossRef
  • Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer
    Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Hutarew, Maximilian Hochmair, Gudrun Absenger, Luka Brcic, Leonhard Müllauer, Gerhard Dekan, Ulrike Setinek, Dagmar Krenbek, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Rainer Kolb, Gerald Webersinke,
    memo - Magazine of European Medical Oncology.2016; 9(4): 191.     CrossRef
  • 15,842 View
  • 472 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Special Article
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park
Cancer Res Treat. 2016;48(2):458-464.   Published online October 14, 2015
DOI: https://doi.org/10.4143/crt.2015.135
AbstractAbstract PDFPubReaderePub
Purpose
We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post hoc subgroup analysis of that study assessing the demographics and disposition of the Korean patient subgroup, and comparing the tolerability of PC/G and gefitinib monotherapy and the tumor response with respect to epidermal growth factor receptor (EGFR) status.
Materials and Methods
Patients, who were ≥ 18 years, chemonaïve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. Treatment-emergent adverse events (TEAEs) were graded, and tumor response was measured as change in lesion sum from baseline at best response. The study was registered with ClinicalTrials. gov, NCT01017874.
Results
Overall, 111 Korean patients were treated (PC/G, 51; gefitinib, 60). Between-arm characteristics were balanced and similar to those of the overall population. Treatment discontinuations due to adverse events were low (PC/G: 1, 2.0%; gefitinib: 7, 11.7%). Overall, 92 patients (82.9%) reported ≥ 1 TEAE (PC/G, 44; gefitinib, 48); few patients (PC/G, 16; gefitinib, 7) reported severe TEAEs; the most frequent was neutropenia (PC/G arm) and elevated alanine aminotransferase (gefitinib arm). The lesion sum was decreased by PC/G treatment in most patients, regardless of EGFRmutation status, while gefitinib monotherapy reduced the lesion sum in EGFR-positive patients but had no effect in EGFR-negative patients.
Conclusion
Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy.

Citations

Citations to this article as recorded by  
  • Gefitinib for advanced non-small cell lung cancer
    Esther HA Sim, Ian A Yang, Richard Wood-Baker, Rayleen V Bowman, Kwun M Fong
    Cochrane Database of Systematic Reviews.2018;[Epub]     CrossRef
  • 12,287 View
  • 141 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Review Article
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Joon Oh Park, Do-Youn Oh, Chiun Hsu, Jen-Shi Chen, Li-Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim
Cancer Res Treat. 2015;47(3):343-361.   Published online May 18, 2015
DOI: https://doi.org/10.4143/crt.2014.308
AbstractAbstract PDFPubReaderePub
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.

Citations

Citations to this article as recorded by  
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): 73.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): e67.     CrossRef
  • Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone
    Masaaki Kagoura, Shin Kobayashi, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi, Naoto Gotohda
    European Journal of Surgical Oncology.2024; 50(3): 107980.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): e213.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): 231.     CrossRef
  • Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    Howard A Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, Valeriy Breder, Jean-Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do-Y
    The Lancet Oncology.2024; 25(5): 626.     CrossRef
  • Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models
    Niranjan Awasthi, Lily Darman, Margaret A. Schwarz, Roderich E. Schwarz
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
    Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
    Nature Communications.2023;[Epub]     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): e92.     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): 420.     CrossRef
  • Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Susanna Slater, David Cunningham
    The Lancet.2023; 401(10391): 1826.     CrossRef
  • Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
    Jihye L. Golino, Xin Wang, Jing Bian, Benjamin Ruf, Michael Kelly, Baktiar O. Karim, Maggie C. Cam, Changqing Xie
    Cancers.2023; 15(9): 2454.     CrossRef
  • Very rare metastatic phenomena of biliary tract cancer to the cerebellum: A case report and review of the literature
    Oadi N. Shrateh, Shadi Abu Saa
    International Journal of Surgery Case Reports.2023; 111: 108819.     CrossRef
  • Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
    Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang
    Biomedicines.2023; 11(11): 2933.     CrossRef
  • Effectivity of Palliative Care Bundle on Advanced Gallbladder Cancer: A Randomised Controlled Trial
    Kusum K. Rohilla, C. Vasantha Kalyani, Amit Gupta, Manoj Gupta, Nirmal Matella
    Indian Journal of Palliative Care.2023; 29: 447.     CrossRef
  • Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
    Wen-Hui Luo, Shao-Jun Li, Xue-Feng Wang
    World Journal of Gastrointestinal Oncology.2023; 15(11): 2033.     CrossRef
  • S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): e186.     CrossRef
  • S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome
    M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A
    Zeitschrift für Gastroenterologie.2022; 60(02): 219.     CrossRef
  • Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
    Jianyang Fu, Nicole A McGrath, Jihye Lee, Xin Wang, Gagandeep Brar, Changqing Xie
    Hepatobiliary & Pancreatic Diseases International.2022; 21(5): 485.     CrossRef
  • Cytotoxic activities of ethanolic crude extracts from fruiting bodies of bamboo mushrooms (Dictyophora spp.) against cholangiocarcinoma cells
    Pathanin Chantree, Sirilak Chumkiew, Mantana Jamklang, Pongsakorn Martviset
    Research Results in Pharmacology.2022; 8(1): 33.     CrossRef
  • LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
    Eunsil Sung, Minkyung Ko, Ju-young Won, Yunju Jo, Eunyoung Park, Hyunjoo Kim, Eunji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Da-som Choi, Seunghyun Choi, Youngeun Hong, Hyeyoung Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghw
    Molecular Therapy.2022; 30(8): 2800.     CrossRef
  • Toripalimab in advanced biliary tract cancer
    Wei Li, Yueqi Wang, Yiyi Yu, Qian Li, Yan Wang, Chenlu Zhang, Xiaojing Xu, Xi Guo, Yu Dong, Yuehong Cui, Qing Hao, Lujia Huang, Houbao Liu, Tianshu Liu
    The Innovation.2022; 3(4): 100255.     CrossRef
  • Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
    Sedighe Hosseini Shabanan, Nariman Nezami, Mohamed E. Abdelsalam, Rahul Anil Sheth, Bruno C. Odisio, Armeen Mahvash, Peiman Habibollahi
    Current Oncology.2022; 29(6): 3825.     CrossRef
  • Can patients with gallbladder adenocarcinoma and liver metastases obtain survival benefit from surgery? A population-based study
    Tianming Gao, Hua Tang, Baohuan Zhou, Dousheng Bai, Shengjie Jin, Chi Zhang, Guoqing Jiang
    Updates in Surgery.2022; 74(4): 1353.     CrossRef
  • Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
    Koushik Sarker , Avijit Ghosh , Abhijit Saha, Suvasish Mishra, Subrata Sen
    Letters in Drug Design & Discovery.2022; 19(4): 314.     CrossRef
  • Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways
    Michael J. Viereckl, Kelsey Krutsinger, Aaron Apawu, Jian Gu, Bryana Cardona, Donovan Barratt, Yuyan Han
    Biomolecules.2022; 12(6): 854.     CrossRef
  • Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment
    Karlijn Verkerk, Hans-Martin Otten, Alwin D. R. Huitema
    Cancer Chemotherapy and Pharmacology.2022; 90(5): 417.     CrossRef
  • Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines
    Jiaqi Yang, David Sontag, Yuewen Gong, Gerald Y Minuk
    Journal of Gastroenterology and Hepatology.2021; 36(4): 1103.     CrossRef
  • Biliary tract cancer
    Juan W Valle, R Katie Kelley, Bruno Nervi, Do-Youn Oh, Andrew X Zhu
    The Lancet.2021; 397(10272): 428.     CrossRef
  • Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
    Changhoon Yoo, Sang Hyun Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, Jae Hoon Lee
    Cancers.2021; 13(7): 1647.     CrossRef
  • Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma
    A.A. Pechetov, A.V. Chzhao, Sh.V. Ragimov, D.A. Volchansky, M.A. Makov, B.N. Gurmikov
    Onkologiya. Zhurnal imeni P.A.Gertsena.2021; 10(2): 39.     CrossRef
  • IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA
    Hung-Chune Maa, Yi-No Wu
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 80.     CrossRef
  • Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma
    Lynn E. Nooijen, Lotte C. Franken, Ali Belkouz, Ikrame Oulad Abdennabi, Marc G. Besselink, Olivier R. Busch, Rutger-Jan Swijnenburg, Heinz-Josef Klümpen, Joris I. Erdmann
    American Journal of Clinical Oncology.2021; 44(10): 526.     CrossRef
  • Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
    Ranu S Sinniah, Mark S Shapses, Mohammad Umar Ahmed, Hani Babiker, Sreenivasa R. Chandana
    Expert Opinion on Investigational Drugs.2021; 30(10): 1047.     CrossRef
  • RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
    Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
    Journal of Clinical Medicine.2021; 10(20): 4652.     CrossRef
  • Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR
    Yang Yang, Jigang Li, Lei Yao, Lile Wu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin, Sheng Yan
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie
    Sabrina Voesch, Michael Bitzer, Nisar Peter Malek
    Deutsches Ärzteblatt Online.2021;[Epub]     CrossRef
  • Treatment of advanced gallbladder cancer: A SEER‐based study
    Weipu Mao, Fang Deng, Dongyan Wang, Li Gao, Xiuquan Shi
    Cancer Medicine.2020; 9(1): 141.     CrossRef
  • LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
    Sheng Shen, Jiwen Wang, Bohao Zheng, Ying Tao, Min Li, Yueqi Wang, Xiaoling Ni, Tao Suo, Houbao Liu, Han Liu, Jiwei Zhang
    Molecular Therapy - Nucleic Acids.2020; 19: 446.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer
    Jie Wang, Xiaobo Bo, Changcheng Wang, Yanlei Xin, Lingxi Nan, Rongkui Luo, Lingli Chen, Xiao Shi, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Pinxiang Lu, Yueqi Wang, Houbao Liu
    Cancer Science.2020; 111(1): 219.     CrossRef
  • Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai
    World Journal of Gastrointestinal Oncology.2020; 12(1): 83.     CrossRef
  • Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer
    Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek,
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1063.     CrossRef
  • NUC-1031 in biliary tract cancer: from bench to bedside and back?
    Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti
    Cancer Chemotherapy and Pharmacology.2020; 85(6): 1011.     CrossRef
  • Targeting cancer stem cells in cholangiocarcinoma (Review)
    Nicole Mcgrath, Jianyang Fu, Sophie Gu, Changqing Xie
    International Journal of Oncology.2020; 57(2): 397.     CrossRef
  • Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
    Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane
    BMC Cancer.2020;[Epub]     CrossRef
  • Combined treatment for locally advanced cholangiocellular liver cancer - the case report
    A. N. Polyakov, Yu. I. Patyutko, A. Yu. Syskova, K. A. Romanova, I. S. Bazin, O. N. Sergeeva, E. R. Virshke, E. S. Makarov, E. Yu. Antonova, A. A. Kirshin, D. V. Podluzhnyi
    Research and Practical Medicine Journal.2019; 6(4): 158.     CrossRef
  • Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin
    J. Dierks, M. P. Gaspersz, A. Belkouz, J. L. A. van Vugt, R. J. S. Coelen, J. W. B. de Groot, A. J. ten Tije, W. G. Meijer, J. F. M. Pruijt, T. van Voorthuizen, D. J. van Spronsen, M. Rentinck, D. ten Oever, J. M. Smit, H. M. Otten, T. M. van Gulik, J. W.
    Acta Oncologica.2018; 57(6): 807.     CrossRef
  • Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
    Jae Woo Lee, Yong-Tae Kim, Sang Hyub Lee, Jun Hyuk Son, Jin Woo Kang, Ji Kon Ryu, Dong Kee Jang, Woo Hyun Paik, Ban Seok Lee
    Gut and Liver.2018; 12(1): 102.     CrossRef
  • Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
    Xiaobo Bo, Jie Wang, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Yueqi Wang, Houbao Liu, Jiejie Xu
    BMC Cancer.2018;[Epub]     CrossRef
  • Revision of bilateral self-expandable metallic stents placed using the stent-in-stent technique for malignant hilar biliary obstruction
    Jun Hyuk Son, Hee Seung Lee, Sang Hyub Lee, Seungmin Bang, Jinwoo Kang, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
    Hepatobiliary & Pancreatic Diseases International.2018; 17(5): 437.     CrossRef
  • Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms
    G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann
    Der Chirurg.2018; 89(11): 858.     CrossRef
  • Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer
    Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Sc
    World Journal of Surgery.2017; 41(1): 224.     CrossRef
  • Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study
    Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Celaletdin Camci
    Journal of Gastrointestinal Cancer.2017; 48(2): 170.     CrossRef
  • SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts
    Changzheng Wang, Hongwei Lv, Wen Yang, Ting Li, Tian Fang, Guishuai Lv, Qin Han, Liwei Dong, Tianyi Jiang, Beige Jiang, Guangshun Yang, Hongyang Wang
    Cancer Letters.2017; 398: 1.     CrossRef
  • Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer
    Yoshiki Hirooka, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Koji Nonogaki, Akira Kanamori, Takanori Hirai, Hiroki Uchida, Osamu Shirai, Hideki Ishikawa, Hidemi Goto
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 119.     CrossRef
  • CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
    Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
    Cancer Research and Treatment.2017; 49(3): 807.     CrossRef
  • Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients
    Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu-pyo Kim, Seong-Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Hyungwoo Cho, Baek-Yeol Ryoo, Heung-Moon Chang
    Cancer Chemotherapy and Pharmacology.2017; 80(1): 209.     CrossRef
  • Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis
    Jonghun John Lee, Sebastian T Schindera, Hyun-Jung Jang, Scott Fung, Tae Kyoung Kim
    Abdominal Radiology.2017; 42(12): 2898.     CrossRef
  • Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution
    Byoung Hyuck Kim, Eui Kyu Chie, Kyubo Kim, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang, Sung W. Ha
    Oncotarget.2017; 8(44): 78076.     CrossRef
  • The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
    Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
    Oncotarget.2017; 8(59): 100657.     CrossRef
  • Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute
    Vineet Talwar, Shubhra Raina, Varun Goel, Dinesh C. Doval
    International Journal of Hepatobiliary and Pancreatic Diseases.2017; 7(2): 1.     CrossRef
  • Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
    Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, Yan-Shen Shan, Shiu-Feng Huang, Li-Tzong Chen
    Scientific Reports.2016;[Epub]     CrossRef
  • Chemotherapy for advanced biliary tract carcinoma
    Lawrence Chen, Chiehfeng Chen, Yun Yen, Ka-Wai Tam
    Medicine.2016; 95(33): e4584.     CrossRef
  • The role of microRNAs in gallbladder cancer
    GANGHUA YANG, LEI ZHANG, RUIXIANG LI, LIN WANG
    Molecular and Clinical Oncology.2016; 5(1): 7.     CrossRef
  • 18,174 View
  • 215 Download
  • 70 Web of Science
  • 66 Crossref
Close layer
Special Article
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
Cancer Res Treat. 2015;47(4):549-554.   Published online April 29, 2015
DOI: https://doi.org/10.4143/crt.2014.362
AbstractAbstract PDFPubReaderePub
Advances in oncology research have led to identification of tumor-specific biomarkers, some of which are important predictive indicators and ideal targets for novel therapeutics. One such biomarker in non-small cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR). Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. The prevalence of EGFR mutations in East Asian patients is higher than that in other populations, and in some clinical settings, patients have been treated with EGFR inhibitors based on clinicopathologic characteristics with no information on EGFR status. However, based on results from a series of studies in which East Asian patients with advanced non-squamous NSCLC were treated with EGFR inhibitors alone or in combination with standard chemotherapy, this may not be the best practice because EGFRmutation status was found to be a key predictor of outcome. Data from these studies highlight the necessity of EGFR testing in determining the most suitable treatment for patients with advanced or metastatic NSCLC.

Citations

Citations to this article as recorded by  
  • Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer
    HM Huang, Y Wei, JJ Wang, FY Ran, Y Wen, QH Chen, BF Zhang
    Balkan Journal of Medical Genetics.2023; 25(2): 29.     CrossRef
  • EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
    Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
    Cancer Research and Treatment.2018; 50(3): 908.     CrossRef
  • Traditional Korean Medicine for Skin Toxic Side Effects from Afatinib in a Non-Small Cell Lung Cancer Patient: A Case Report
    So-hyun Shim, Hee-jeong Seo, Jin-yong Choi, Go-eun Bae, Hyung-bum Seo, So-yeon Kim, Chang-woo Han, Seong-ha Park, Young-ju Yun, In Lee, Jung-nam Kwon, Jin-woo Hong, Jun-yong Choi
    The Journal of Internal Korean Medicine.2018; 39(5): 973.     CrossRef
  • MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
    Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
    Journal of Thoracic Oncology.2017; 12(8): 1233.     CrossRef
  • Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics
    Ali Sabri, Madiha Batool, Zhaolin Xu, Drew Bethune, Mohamed Abdolell, Daria Manos
    European Radiology.2016; 26(11): 4141.     CrossRef
  • Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
    Boram Lee, Taebum Lee, Se-Hoon Lee, Yoon-La Choi, Joungho Han
    Oncotarget.2016; 7(17): 23874.     CrossRef
  • The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
    Yaxiong Zhang, Dacheng He, Wenfeng Fang, Shiyang Kang, Gang Chen, Shaodong Hong, Jin Sheng, Jianhua Zhan, Nan Chen, Zhihuang Hu, Cong Xue, Yunpeng Yang, Yuxiang Ma, Tao Qin, Ting Zhou, Yan Huang, Li Zhang
    Medicine.2015; 94(44): e1949.     CrossRef
  • 12,543 View
  • 86 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
Original Articles
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Dae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlando
Cancer Res Treat. 2015;47(4):616-629.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.051
AbstractAbstract PDFPubReaderePub
Purpose
This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-based trends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamous non-small cell lung cancer (NSCLC).
Materials and Methods
Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). The primary endpoint, progression-free survival (PFS), was analyzed using a multivariate Cox model.
Results
Consistent with the results of the overall study, a statistically significant difference in PFS among the three arms was noted in the EA population favoring pemetrexed-erlotinib (overall p=0.003) as compared with either single-agent arm (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29 to 0.79; p=0.004 vs. erlotinib; HR, 0.40; 95% CI, 0.23 to 0.70; p=0.001 vs. pemetrexed). The EA patients treated with pemetrexed-erlotinib achieved a longer median PFS (7.4 months) compared with erlotinib (4.5 months) and pemetrexed (4.0 months). The PFS results also numerically favored pemetrexed-erlotinib in the non-EA population (overall p=0.210) (HR, 0.62; 95% CI, 0.37 to 1.05; p=0.078 vs. erlotinib; HR, 0.75; 95% CI, 0.42 to 1.32; p=0.320 vs. pemetrexed) (median PFS: pemetrexed-erlotinib, 6.7 months; erlotinib, 3.0 months; pemetrexed, 4.4 months).
Conclusion
The PFS results from this subset analysis in both EA and non-EA populations are consistent with the results in the overall population. The PFS advantage for pemetrexed-erlotinib is significant compared with the single agents in EA patients.

Citations

Citations to this article as recorded by  
  • Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
    Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition
    Elisabeth Smolle, Martin Pichler
    Cancers.2019; 11(2): 204.     CrossRef
  • Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
    Pteridines.2019; 30(1): 171.     CrossRef
  • A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
    James Chih-Hsin Yang, Tony Mok, Baohui Han, Mauro Orlando, Tarun Puri, Keunchil Park
    Clinical Lung Cancer.2018; 19(1): 27.     CrossRef
  • Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
    Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu G. Bathini, Huiyu Wen, Kaili Zhou, Patricia B. Pasquinelli, Srikanth Gajavelli, Meera Sreedhara, Xianhong Xie, Primo N. Lara, David R. Gandara,
    Clinical Lung Cancer.2017; 18(1): 60.     CrossRef
  • Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
    Haihong Yang, Qiuhua Deng, Yuan Qiu, Jun Huang, Yubao Guan, Fengnan Wang, Xin Xu, Xinyun Yang
    ESMO Open.2017; 2: e000112.     CrossRef
  • Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
    Jung Ran Choi, Seong Yong Park, O Kyu Noh, Young Wha Koh, Dae Ryong Kang
    Annals of Occupational and Environmental Medicine.2016;[Epub]     CrossRef
  • Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
    Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
    Cancer Research and Treatment.2015; 47(4): 549.     CrossRef
  • 12,702 View
  • 137 Download
  • 8 Crossref
Close layer
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
James Chin-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa, Tomohide Tamura, Helen Barraclough, Sotaro Enatsu, Rebecca Cheng, Mauro Orlando
Cancer Res Treat. 2015;47(3):424-435.   Published online September 15, 2014
DOI: https://doi.org/10.4143/crt.2013.266
AbstractAbstract PDFPubReaderePub
Purpose
A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). The majority of patients enrolled in PARAMOUNT were Caucasian (94%). We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC. Materials and Methods Study S110 was a phase II, multicenter, randomized, controlled, open-label trial in never-smoker, chemonaïve, EA patients (n=31) with locally advanced or metastatic nonsquamous NSCLC (n=27). Study JMII was a multicenter, open-label, single-arm, postmarketing, clinical trial in Japanese patients (n=109) with advanced nonsquamous NSCLC. PARAMOUNT was a multicenter, randomized, double-blind, placebo-controlled trial in patients with advanced nonsquamous NSCLC. Results In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. The median PFS for pemetrexed continuation maintenance therapy in PARAMOUNT was 4.1 months (95% CI, 3.2 to 4.6 months). Pemetrexed continuation maintenance therapy in EA patients in studies S110 and JMII did not lead to any unexpected safety events, and was consistent with PARAMOUNT’s safety profile. Conclusion The efficacy and safety data in the EA trials were similar to those in PARAMOUNT despite differences in patient populations and study designs. These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC.

Citations

Citations to this article as recorded by  
  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
    Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng L
    The Lancet Respiratory Medicine.2021; 9(3): 305.     CrossRef
  • Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
    Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
    Xiaoqing Yu, Yun Fan
    Medicine.2019; 98(3): e14110.     CrossRef
  • Best Practices in Treatment Selection for Patients with Advanced NSCLC
    Mark A. Socinski, Nathan A. Pennell
    Cancer Control.2016; 23(4_suppl): 2.     CrossRef
  • 13,971 View
  • 103 Download
  • 4 Web of Science
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP